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ABSTRACT
Background. Recommendations for intraoperative and
postoperative breast sentinel lymph node (SLN) processing
differ widely. Micrometastases and isolated tumor cells
(ITC) have recently been proposed as prognostically and
therapeutically relevant. We compared 3 SLN protocols
with regard to intraoperative and postoperative diagnosis.
Materials and Methods. SLN in cohort I (270 patients)
were intraoperatively assessed by stereomicroscopy.
Intraoperative frozen section (IFS) was used only in ste-
reomicroscopically suspicious SLN. In cohort II (197
patients), all SLN were examined with only 1 IFS. Final
SLN workup in cohorts I and II consisted of complete step
sectioning with immunohistochemistry. In cohort III (268
patients) 2 or more IFS were performed followed by 3 step
sections and immunohistochemistry.
Results. pN1 stages were significantly higher in cohorts I
and II (33.3% and 34.0% respectively) than in cohort III
(24.6%). Intraoperative false negativity for the detection of
metastases (pN1) ranged from 54.4% (cohort I) and 35.8%
(cohort II) to 21.2% (cohort III). In contrast, ITC were
detected significantly more frequently in cohort I (9.3%)
and cohort II (14.7%) than in cohort III (1.9%).
Conclusions. Higher rates of SLN metastases and ITC in
cohort I/II compared to cohort III suggest that IFS may result
in tissue loss thus increasing the risk of missing metastases.
Sparse IFS but complete postoperative SLN workup with
step sectioning and immunohistochemistry provides more
accurate information regarding minimal disease in SLN, but
often results in delayed axillary lymph node dissection. This
is important for preoperative patient information and rec-
ommendations in SLN processing protocols.
The axillary nodal status is one of the most important
prognostic factors in breast cancer.1,2 Intraoperative senti-
nel lymph node (SLN) biopsy is a good predictor of the
axillary nodal status and is now a standard method in the
assessment of patients with early breast cancer.3–6 Despite
the general acceptance of the SLN model, protocols for
intraoperative and postoperative processing of SLN differ
widely.7–11 Intraoperative evaluation ranges from only
gross examination, imprint cytology, 1 single intraopera-
tive frozen section (IFS) to complete intraoperative step
sectioning with steps as small as 50 lm including intra-
operative immunohistochemistry and other molecular-
based methods.12–15 Postoperative evaluation includes
hematoxylin and eosin (H&E) step sections, serial sec-
tioning with or without auxiliary immunohistochemical
stainings.12 The accuracy of IFS and the rate of false
negative intraoperative results depend on the intraoperative
workup of the SLN and the size of the metastasis. Some
studies have demonstrated a good accuracy of IFS for
macrometastases, but not for small metastases or isolated
tumor cells.3,6 Isolated tumor cells (staged as pN0(i ?),
with deposits B0.2 mm) and micrometastases (staged as
pN1mi, with deposits [0.2 to B2.0 mm) have been
assigned separate categories in the TNM staging.16 The
cutoff value of 0.2 mm was chosen arbitrarily. Recently, it
has been suggested that patients with ITC or micrometas-
tases have reduced disease-free survival and may profit
from adjuvant therapy.1,2
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Because of the relevance of minimal metastatic disease
in axillary lymph nodes, the intraoperative and postopera-
tive examination of SLNs is of increasing importance. It is
not surprising that increasing the precision the postopera-
tive SLN workup (e.g., with extensive use of cytokeratin
step sections), will result in more intraoperative false
negative cases, where the tumor was missed on a single or
few H&E sections. The complete intraoperative processing
of the SLN with alternating H&E and cytokeratin step
sections at 50-lm intervals was proposed by Viale et al.13
The Swiss Section of Gynecological Pathologists has rec-
ommended an approach of a single IFS followed by
complete postoperative step sectioning using 200-lm
intervals. Varga et al. have recently proposed the use of a
stereomicroscope for the intraoperative assessment of SLN
and preselection for IFS.9 Stereomicroscopy consists of the
examination of native unstained tissue samples with a
magnification factor between 6 and 40, avoiding potential
tissue loss associated with IFS of SLN.9
In this study, we compared 3 large cohorts of patients
with axillary SLN biopsies. In 1 cohort the primary ste-
reomicroscopic approach with or without IFS was used, the
second cohort was diagnosed using the conventional
approach of a single IFS, and diagnosis for the third cohort
allowed 2 or more step sections for the IFS. The postop-
erative workup varied from 3 step sections to complete step
sectioning.
METHODS
Study Cohorts and Protocols
Cohort I (Stereomicroscopy with 1 Facultative Intra-
operative Frozen Section) This cohort included 270
consecutive breast cancer patients (651 SLN), diagnosed at
the Institute of Surgical Pathology, University Hospital
Zurich from August 2007 until end of July 2008. Sentinel
lymph nodes were detected with standard radioactive tracers,
partially in combination with blue dye.6 SLN from these
patients were processed as follows (Table 1): Axillary SLN
were longitudinally bisected (or sectioned in 2-mm slices in
SLN larger than 5 mm) and primarily assessed with a
stereomicroscope. If the cut surface of the lymph node was
clearly involved by the tumor or highly suspicious for
malignancy, 1 single frozen section of the lymph node was
performed.9 In all other cases, lymph nodes were submitted
to paraffin embedding and complete histological sectioning:
paraffin blocks were completely step sectioned (200-lm
steps) with 1 hematoxylin-eosin (H&E) staining and 1
unstained slide at each step. No residual lymph node
structures remained in the paraffin block. If no tumor was
found on the H&E slides, all unstained slides were
immunostained with pan-cytokeratin (Lu5, 1:250, Roche,
Basel, Switzerland) using standard immunohistochemical
protocols and Ventana Benchmark autostainer platforms
(Ventana, Tucson, AZ). Lymph nodes that were found
positive (pN1) at IFS were fixated with formalin and
embedded in paraffin and stained with 1 H&E. Additional
cytokeratin immunostaining was applied if considered
necessary.
The mean number of lymph nodes per case was 2.4
(median 2; range 1–8). The mean size of the lymph node
was 11.2 mm (median 10 mm). The median size of the
invasive carcinomas in this cohort was 16 mm (mean
19.9 mm). The median size of lymph node metastases was
3.6 mm (mean 5.1 mm; range 0.2–25 mm).
Cohort II (Only One Compulsory Intraoperative Frozen
Section) This cohort included 197 consecutive breast
cancer patients (476 SLN), diagnosed at the Institute of
Surgical Pathology, University Hospital Zurich from
August 2004 until end of July 2005. SLN from these
patients were processed as follows (Table 1): All SLN
were bisected (or sectioned deeper in 2-mm slices if large
enough) and 1 intraoperative frozen section stained with
H&E was performed on each SLN irrespective of the gross
TABLE 1 Three different protocols for the intraoperative and postoperative assessment of sentinel lymph nodes (SLN)
Cohort I Cohort II Cohort III
Longitudinal bisection of the SLN Longitudinal bisection of the SLN Longitudinal bisection of the SLN
Stereomicroscopic examination 1 IFS C2 IFS
Suspicious for cancer Not suspicious Positive Negative Positive Negative
1 IFS No IFS
If positive
1 H&E staining Complete workup of SLN in
H&E step sections (200 lm)
and unstained slides for
cytokeratin
1 H&E
staining
Complete workup of SLN in
H&E step sections (200 lm)
and unstained slides for
cytokeratin
1 H&E
staining
Workup of SLN in 3 H&E
step sections (150 lm)
and 1 cytokeratin
staining
If negative see right
column
IFS intraoperative frozen section, H&E hematoxylin & eosin
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appearance of the SLN. The residual SLN tissue was
submitted to paraffin embedding and complete histological
sectioning as described for cohort I.
The mean number of lymph nodes per case was 2.4
(median 2; range 1–8). The mean size of the lymph node
was 10.2 mm (median 10 mm). The median size of the
invasive carcinomas in this cohort was 16 mm (mean
17.7). The median size of these metastases was 3 mm
(mean 4.8 mm; range 0.2–20 mm).
Cohort III (At Least Two or More Intraoperative Frozen
Sections) This group included 268 consecutive breast
cancer patients (472 SLN), diagnosed at the Institute of
Pathology, Charite´ University Hospital Berlin from August
2007 until end of July 2008. SLN from these patients were
examined as follows (Table 1): All SLN were bisected (or
sectioned in 2-mm slices in larger SLN). At least 2
(optionally more) IFS with H&E were performed on each
SLN regardless of the gross appearance of the SLN. If the IFS
was positive, the residual SLN tissue was embedded in
paraffin and only 1 H&E stain was made. If the IFS was
negative, residual SLN tissue was submitted to paraffin
embedding and 3 H&E step sections (150-lm steps) were
performed, accompanied by 1 pan-cytokeratin immunostain-
ing (MNF116, 1:1000, Dako, Glostrup, Denmark) using
Benchmark XT autostainers (Ventana).
The mean number of lymph nodes per case was 1.8
(median 1; range 1–7). The mean size of the lymph node
was 11.4 mm (median 10 mm). The median size of the
invasive carcinomas in this cohort was 18 mm (mean
20.3 mm). The median size of metastases was 5 mm (mean
6.9 mm; range 0.2–35 mm).
Assessment of Potential Tissue Loss
To evaluate the potential effects of tissue loss on the
number and size of lymph node metastasis we analyzed 2
subgroups of the cohorts I and II. The first subgroup
comprised all cases from cohort I that were inconspicuous
in stereomicroscopy and thus left uncut in the IFS. The
second group included cases that had 1 single IFS from
cohort I and II but were considered negative in the IFS.
Statistical Analyses
We analyzed the sensitivity, specificity, positive and
negative predictive values, and accuracy of each protocol.
Further, we assessed differences between the cohorts and
for cases with and without IFS concerning nodal metastases
and presence of ITC. Furthermore, all 3 cohorts were
compared in terms of clinicopathological data to ensure
comparability (Mann–Whitney U). Statistical analyses
TABLE 2 Tumor and lymph node characteristics of cohorts I, II, and III
Parameter Cohort I (%) Cohort II (%) Cohort III (%)
Number of cases 270 (100%) 197 (100%) 268 (100%)
Tumor histology
Invasive ductal carcinoma 216 (80.0%) 162 (82.2%) 209 (78.0%)
Invasive lobular carcinoma 42 (15.6%) 29 (14.7%) 41 (15.3%)
Other cancer types 12 (4.4%) 6 (3.0%) 18 (6.7%)
pT statusa
pT1 170 (63.0%) 138 (70.1%) 163 (60.8%)
pT2 85 (31.5%) 53 (26.9%) 93 (34.7%)
pT3 14 (5.2%) 5 (2.5%) 11 (4.1%)
Multifocal (m)b 29 (10.7%) 19 (9.7%) 35 (13.1%)
Histological tumor gradinga
G1 48 (17.8%) 48 (24.4%) 51 (19.0)
G2 127 (47.0%) 93 (47.2%) 157 (58.6)
G3 88 (32.6%) 53 (26.9%) 58 (21.6)
Patient nodal status
pN0/pN0 i? 155 (57.4%)/25 (9.3%) 101 (51.3%)/29 (14.7%) 197 (73.5%)/5 (1.9%)
pN1 90 (33.3%) 67 (34.0%) 66 (24.6%)
a No pT status was available for 1 case in each cohort, and no grade was given for 7 cases in cohort I, 3 cases in cohort II, and 2 cases in cohort
III
b Multifocal tumors were extracted from other pT stages for comparative reasons and were otherwise included with the pT stage that matched
with the largest tumor nodule
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were performed using Microsoft Excel 2007 and SPSS
Version 18.0. P values \ .05 were considered significant.
RESULTS
Comparability of the Cohorts
There was no statistically significant difference con-
cerning the basic tumor parameters tumor type, pT status
and histological grading between cohorts I and II (Table 2).
A high pT status was significantly more frequent in cohort
III than in cohort II (P = .031). The histological grade was
higher in cohort I than in cohort III (P = .019). There was
no statistical difference between the combined cohorts I
and II and cohort III.
Definitive Diagnosis—More Frequent pN1 Stages
and ITC in Cohort I and II
Cohorts I and II comprised 270 and 197 breast cancer
patients with 90 and 67 lymph node metastases, respec-
tively (Table 2). The frequency of pN1 stages did not differ
between these 2 cohorts (33.3% vs. 34.0%). Isolated tumor
cells (ITC) were slightly more frequent in cohort II (14.7%)
than in cohort I (9.3%). Cohorts I and II (0 or 1 IFS) were
compared with cohort III (n = 268) with 2 or more IFS.
The frequency of patients with positive SLN (pN1) was
significantly lower in cohort III (24.6%) than in cohort I
(33.3%; P = .016), cohort II (34%; P = .027) or cohort I
and II combined (P = .008). ITC were detected in 5
patients (1.9%) of cohort III. This was significantly less
than in cohorts I (9.3%) and II (14.7%), either taken soli-
tary or in a combined analysis (each P \ .001).
Intraoperative Diagnosis—False Negativity
is Related to Sparse IFS
The sensitivity of the IFS for the detection of metastatic
deposits was higher in cohort II (64.2%) compared with
cohort I (45.6%, Table 3). Likewise the negative predictive
value (NPV) (84.3% versus 78.6%) and the accuracy
(87.3% versus 81.9%) were higher in cohort II. Specificity
and positive predictive values (PPV) were between 97.7%
and 100% in both cohorts. In cohort II, 1 IFS was false
positive because of a misinterpretation of large cells with
mitotic figures as micrometastasis. Histological tumor type
was not a relevant factor in any of the 3 protocols for
intraoperative or postoperative detection of metastasis.
Representative cases of corresponding stereomicroscopic
and histological results are displayed in Fig. 1. Theses
cases also demonstrate typical difficulties encountered with
stereomicroscopic assessments.
With 78.8%, the sensitivity of IFS in cohort III was
clearly above that of cohort I and II. The NPV (93.5%) and
accuracy (94.8%) in cohort III were also distinctly above
that of either of the other cohorts. Specificity and PPV were
100%. One SLN was intraoperatively false positive
because of the misinterpretation of an adenosis nodule.
Within cohort I, lymph node metastases were more
frequent in those lymph nodes without an IFS (cohort I)
compared with SLN with 1 IFS (cohort I and II; 13.9% vs.
7.6%; P = .002; Table 4), whereas ITC were only slightly
more often detected in the group with IFS (5.3% vs. 8%).
DISCUSSION
The 3 different protocols for axillary SLN processing
analyzed in this study revealed significantly higher rates of
SLN metastases and ITC in protocols with few IFS com-
bined with complete postoperative workup. In contrast, few
TABLE 3 Comparison of intraoperative frozen section diagnosis
with final diagnosis (after formalin fixation and paraffin embedding)
Intraoperative result Final result Sum
Positive Negative
Cohort I, section 1
Positive 41 (45.6%) 0 (0%) 41
Negative 49 (54.4%) 180 (100%) 229
Sum 90 (100%) 180 (100%) 270
Cohort I, section 2
Positive 48 (37.2%) 0 (0%) 48
Negative 81 (62.8%) 522 (100%) 603
Sum 129 (100%) 522 (100%) 651
Cohort II, section 1
Positive 43 (64.2%) 1 (0.8%) 44
Negative 24 (35.8%) 129 (99.2%) 153
Sum 67 (100%) 130 (100%) 197
Cohort II, section 2
Positive 62 (68.9%) 1 (0.3%) 63
Negative 28 (31.1%) 385 (99.7%) 413
Sum 90 (100%) 386 (100%) 476
Cohort III, section 1
Positive 52 (78.8%) 0 (0%) 52
Negative 14 (21.2%) 202 (100%) 216
Sum 66 (100%) 202 (100%) 268
Cohort III, section 2
Positive 75 (83.3%) 1 (0.3%) 76
Negative 15 (16.7%) 381 (99.7%) 396
Sum 90 (100%) 382 (100%) 472
Section 1 displays the patient result irrespective of the number of
lymph nodes submitted to frozen section. Section 2 depicts the results
for single lymph nodes, since often more than 1 sentinel lymph node
was submitted
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IFS increased the rate of intraoperative false negative SLN
diagnosis with the potential consequence of delayed axil-
lary lymph node dissection. The protocol of SLN
processing is therefore relevant in the debate of short- or
long-term outcome data of clinical trials.2,17
Very recently, de Boer et al. presented a large study
demonstrating that patients with ITC had decreased
disease-free survival and that chemotherapy improved
survival in these patients.2 This study renewed interest in
the implications of the presence of ITC.18–20 Our study
demonstrates how significantly the results of the SLN
biopsy are influenced by the pathological workup protocol
applied. We found a more than 4-fold difference between
cohort III and the other 2 cohorts in the detection of ITC.
Because this study was observational in design, this cer-
tainly implicates potential biases of the results. However,
our analyses of the most important tumor parameters (pT
status, grading, tumor type) did not reveal relevant differ-
ences between the 3 cohorts that could explain such
variances. Therefore, the demonstrated differences in the
amount of ITC are almost certainly the result of the lesser
extent of immunohistological workup in cohort III. This
implies that the validity of results of clinical trials studying
the association of ITC and outcome of breast cancer should
take into account the extent of the SLN workup in
FIG. 1 Stereomicroscopic and
matching histological results
(magnification 69, inlet 2009).
a SLN with macrometastasis
visible in stereomicroscopy (A1)
and in the matching H&E staining
(A2). b Stereomicroscopically
suspect SLN (B1) with fibrosis
and lipomatosis in the histological
section (B2).
c Stereomicroscopically
unsuspicious SLN (C1) with
macrometastasis on the first H&E
section (C2)
TABLE 4 Comparison of lymph node status in sentinel lymph nodes
without intraoperative frozen section (cohort 1) and with intraopera-
tive frozen section (cohort 1 and 2 combined)
Parameter One IFS
performed (%)
No IFS
performed (%)
P value
Lymph node status .002
pN0/pN0 i? 420 (84.3%)/
40 (8.0%)
412 (80.8%)/
27 (5.3%)
pN1 38 (7.6%) 71 (13.9%)
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pathology. The biological relevance of ITC has not been
clearly determined yet.21–24 Rutgers suggested only using
SLN processing protocols that identify lymph node
metastases of known clinical relevance.25 Different SLN
protocols in various breast centers, sufficient follow-up
time, and adequate clinical screening for metastases are
potential limitations and prerequisites of clinical studies to
evaluate the relationship between ITC or micrometastases
with clinical outcome.26
Our results further show that 2 or more intraoperative
step sections resulted in a better intraoperative sensitivity
to detect lymph node metastases compared with a single
IFS-only model, which can be regarded as a clear argument
to use 2 or more intraoperative step sections. Higher
intraoperative sensitivity and accuracy are helpful to avoid
delayed axillary lymph node dissection, thereby lowering
iatrogenic morbidity. Importantly, our findings suggest that
a higher intraoperative detection rate for metastases with
more than 1 IFS was also accompanied by a significantly
lower rate of metastases in the final diagnosis. This sup-
ports the hypothesis that tissue loss occurs during the
procedure of IFS, which might have been the reason for
recommendations in the United Kingdom of not perform-
ing IFS.9,12 To avoid tissue loss was also the basic concept
for using stereomicroscopic preselection of SLN for IFS as
described by Varga et al.9
Concerning stereomicroscopy, our data suggest that the
macroscopic/stereomicroscopic preselection of SLN cannot
be recommended, because this approach does not lead to
significantly higher rates of postoperatively detected
metastases compared with a protocol with a single IFS.
Instead stereomicroscopic preselection led to a very high
rate of intraoperative false negativity (54.4%). As seen in
Fig. 1 some metastases are invisible to the naked eye or
stereomicroscopy. Theoretically, specimens with intense
blue dye staining could also make it harder for the
pathologist to interpret the stereomicroscopic results.
However, the latter situation constituted no major problem
in our experience. Because the cohorts without or with 1
IFS showed similar rates of pN1 stages (33.3% vs. 34%)
and ITC (14.7% vs. 9.3%), this supports a recommendation
to do at least 1 IFS intraoperatively. Nonetheless, it has to
be noted that the intraoperative false negativity rate with a
single IFS was still high (35.8%) compared with the use of
2 and more IFS (21.2%). This phenomenon can be
explained by the location of the metastatic deposits in
deeper planes of the SLN. Because a single IFS only
detects metastases located on the cutting plane of the
lymph node, we analyzed how many of the metastases were
found on the cutting plane and how many on deeper step
sections only. From 157 patients with SLN metastases in
cohorts I and II, 48 (30.6%) were not detectable on the first
step section. From the 54 patients where ITC were the only
finding, for 28 (51.9%) cases the ITC were only detectable
on deeper step sections. Figure 2 illustrates the problem
of metastases in deeper cutting planes. None of the pro-
tocols showed any tumor type specific advantages or
disadvantages.
Economical questions have to be also taken into account
for the recommendation of SLN processing protocol. Viale
et al. propose the complete intraoperative processing of the
SLN with alternating H&E and cytokeratin step sections at
50 lm intervals.13 Considering that the number of SLN
submitted might easily exceed 1 or 2, the costs and time of
such a complete intraoperative workup as well as the
obligation to meet also the intraoperative demands of other
surgical specialities, such a protocol is difficult to imple-
ment in a cost- and time-efficient way in most pathology
laboratories. Although we did not specifically compare the
exact IFS times of the protocols, in this context it should be
noted that none of the 3 evaluated protocols exceeded a 30-
minute time limit for IFS.
In conclusion, our presented data support a strong
dependence between the use of IFS and extent of step
sectioning with intraoperative sensitivity/accuracy and
potential tissue loss. Some surgeons believe that the pos-
sibility for an axillary lymph node dissection during initial
surgery outweighs the risk of missed metastases.6,27 In our
opinion, this is a point that should be decided under con-
sideration of the patients physical condition and
preferences. The highest rate of metastasis detection is
reached by omission of IFS or a single IFS followed by a
thorough and immunohistochemically supported workup of
the SLN. Stereomicroscopic-based assessment could not be
recommended due to high intraoperative false negativity. If
the presence of ITC should become decisive for treatment
selection, the current high variability of protocols in the
detection of ITC has to be seriously reconsidered.
FIG. 2 Two step-sectioned SLN with different tumor localizations.
In contrast to the macrometastasis (arrowhead) in SLN a, maximum
in the cutting plane, the 1 in SLN b would probably be missed by
stereoscopic or single IFS assessment. Detecting micrometastases or
ITC (arrows) is a challenge in the H&E staining regardless of the
localization
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